BNGO NASDAQ
Bionano Genomics, Inc.
1W: -2.4%
1M: -27.4%
3M: +11.9%
YTD: -23.3%
1Y: -34.8%
3Y: -98.6%
5Y: -100.0%
$1.22
+0.06 (+5.17%)
Weekly Expected Move ±8.2%
$1
$1
$1
$1
$1
Credit Risk of going bust: higher than 74% of companies Debt: 31.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.06 (down 95%), Bionano Genomics, Inc. would be worth roughly what it owes.
Total debt $6.7M against a stock market value of $14.4M.
Distance to default 3.14 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $3.4M (short-term plus half of long-term), stock volatility 61.4%; Altman Z -22.30. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.06 (down 95%), Bionano Genomics, Inc. would be worth roughly what it owes.
Total debt $6.7M against a stock market value of $14.4M.
Distance to default 3.14 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $3.4M (short-term plus half of long-term), stock volatility 61.4%; Altman Z -22.30. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
13 relationships13
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-10-12
Earliest Filing
2025-02-21
Latest Filing
investor: 7
partner: 3
target: 3
Counterparties (Filed by BNGO)
13 relationshipsCompanies named in BNGO's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Cowen and Company, LLC | — | partner | Former sales agent for the Company's common stock under the terminated Sales Agreement. | 2025-02-21 | View |
| H.C. Wainwright & Co., LLC | — | partner | Sales agent under the new At The Market Offering Agreement for the Company's common stock. | 2025-02-21 | View |
| JGB Partners, LP | — | investor | Holder of Senior Secured Convertible Debenture | 2025-01-03 | View |
| JGB Capital, LP | — | investor | Holder of Senior Secured Convertible Debenture | 2025-01-03 | View |
| JGB Capital Offshore Ltd. | — | investor | Holder of Senior Secured Convertible Debenture | 2025-01-03 | View |
| FourWorld Deep Value Opportunities Fund I, LLC | — | investor | Holder of Senior Secured Convertible Debenture | 2025-01-03 | View |
| Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B | — | investor | Holder of Senior Secured Convertible Debenture | 2025-01-03 | View |
| Canaccord Genuity LLC | — | partner | Exclusive placement agent for the Offering. | 2024-05-28 | View |
| High Trail Special Situations LLC | — | investor | Purchaser of senior secured convertible notes and warrants in a private placement and registered offering. | 2024-02-28 | View |
| High Trail Special Situations LLC | — | investor | Purchaser of senior secured convertible notes and warrants in a registered offering and private placement. | 2023-10-11 | View |
| Purigen Biosystems, Inc. | — | target | Acquired by Bionano Genomics, Inc. via a merger agreement completed on November 30, 2022. | 2022-11-30 | View |
| BioDiscovery, Inc. | — | target | Target company acquired by Bionano Genomics, Inc. via a merger agreement. | 2021-10-19 | View |
| BioDiscovery, Inc. | — | target | Target company to be acquired by Bionano Genomics, Inc. via a two-step merger structure. | 2021-10-12 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-14 | Regulation FD; Exhibits | View | |
| 2026-08-10 | Earnings Release; Exhibits | View | |
| 2026-06-24 | Other Events; Exhibits | View | |
| 2026-06-05 | Officer/Director Change | View | |
| 2026-05-28 | Other Events; Exhibits | View | |
| 2026-05-14 | Shareholder Vote | View | |
| 2026-05-13 | Earnings Release; Exhibits | View | |
| 2026-05-06 | Officer/Director Change; Other Events; Exhibits | View | |
| 2026-03-23 | Earnings Release; Exhibits | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-18 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-08-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-18 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-06-13 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-31 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-21 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-02-10 | Termination of Material Definitive Agreement | View | |
| 2025-01-27 | Material Modification to Rights of Security Holders; Amendments to Articles of Incorporation or Byla | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR